FIELD: biotechnology.
SUBSTANCE: an antibody and fusion protein with specific heavy chain isotypes for use in therapeutic treatment of dogs are presented. The amino acid sequence of the heavy chain minimizes activation of effector functions of the immune system binding an antibody or a fusion protein to the target antigen. Also, methods for purification of the said antibody and the said fusion protein are provided.
EFFECT: invention can be used for treatment of pathological conditions such as pain, inflammatory conditions and cancer conditions of dogs.
16 cl, 15 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC CANINE IMMUNOGLOBULINS AND METHODS FOR THEIR USE | 2012 |
|
RU2626527C1 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2644235C2 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2640252C2 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2640254C2 |
| ANTIBODY AGAINST PD-L1 | 2017 |
|
RU2744862C2 |
| MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-31 | 2012 |
|
RU2588462C2 |
| ANTIBODIES TO CANINE PD-1 | 2014 |
|
RU2761663C2 |
| CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND TNFα ANTAGONIST DOMAIN | 2015 |
|
RU2678810C2 |
| CANINISED MURINE ANTIBODIES TO HUMAN PD-1 | 2014 |
|
RU2676158C1 |
| C5 ANTIBODY AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-RELATED DISEASES | 2014 |
|
RU2663349C2 |
